---
title: "Rabeprazole - Zollinger-Ellison Syndrome"
sidebar: mydoc_sidebar
permalink: db01129-mesh-d015043-1.html
toc: false 
---


Path ID: `DB01129_MESH_D015043_1`
{% include image.html url="images/db01129-mesh-d015043-1.png" file="db01129-mesh-d015043-1.png" alt="db01129-mesh-d015043-1" %}

## Concepts

|------------|------|---------|
| Identifier | Name | Type    |
|------------|------|---------|
| MESH:D064750 | rabeprazole | Drug |
| UniProt:P20648 | Potassium-transporting ATPase alpha chain 1 | Protein |
| GO:0001696 | gastric acid secretion | BiologicalProcess |
| MESH:D005744 | Gastric Acid | ChemicalSubstance |
| HP:0002588 | Duodenal ulcer | PhenotypicFeature |
| HP:0004398 | Peptic ulcer | PhenotypicFeature |
| MESH:D015043 | Zollinger-Ellison syndrome | Disease |
|------------|------|---------|

## Relationships

|---------|-----------|---------|
| Subject | Predicate | Object  |
|---------|-----------|---------|
| Rabeprazole | DECREASES ACTIVITY OF | Potassium-Transporting Atpase Alpha Chain 1 |
| Potassium-Transporting Atpase Alpha Chain 1 | POSITIVELY REGULATES | Gastric Acid Secretion |
| Gastric Acid Secretion | INCREASES ABUNDANCE OF | Gastric Acid |
| Gastric Acid | POSITIVELY CORRELATED WITH | Duodenal Ulcer |
| Gastric Acid | POSITIVELY CORRELATED WITH | Peptic Ulcer |
| Duodenal Ulcer | MANIFESTATION OF | Zollinger-Ellison Syndrome |
| Peptic Ulcer | MANIFESTATION OF | Zollinger-Ellison Syndrome |
|---------|-----------|---------|

Reference: 
  - [https://go.drugbank.com/drugs/DB01129](https://go.drugbank.com/drugs/DB01129)
  - [https://en.wikipedia.org/wiki/Rabeprazole#Mechanism_of_action](https://en.wikipedia.org/wiki/Rabeprazole#Mechanism_of_action)
  - [https://pubchem.ncbi.nlm.nih.gov/compound/5029#section=Mechanism-of-Action](https://pubchem.ncbi.nlm.nih.gov/compound/5029#section=Mechanism-of-Action)
  - [https://en.wikipedia.org/wiki/Zollinger%E2%80%93Ellison_syndrome#Pathophysiology](https://en.wikipedia.org/wiki/Zollinger%E2%80%93Ellison_syndrome#Pathophysiology)
